The results vaulted Nektar’s market value to over $1 billion amid expectations the drug might prove a challenger to widely used medications like Dupixent.

Evommune (EVMN) stock surges as the company posts a mid-stage trial win for its experimental drug targeting atopic dermatitis ...

Investing.com -- Evommune Inc. (NYSE:EVMN) stock soared 64% after the clinical-stage biotechnology company announced positive top-line results from its Phase 2a trial evaluating EVO301 in patients ...

‘Melania’ declines 67% at domestic box office—one week after beating its projections US snowboard star Chloe Kim calls for unity after Trump bashes teammate over immigrant crackdown Retired FBI agent ...

Eczema is a group of inflammatory and chronic skin conditions, and it is the most common skin disease among older people. As many as one in two people aged over 60 suffer from some form of eczema. A ...

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). The journal concluded that ...

Remibrutinib, a BTK inhibitor, offers a new oral treatment for chronic spontaneous urticaria, providing an alternative to traditional therapies. Experts discuss groundbreaking therapies in dermatology ...

Among patients with moderate to severe atopic dermatitis, atopic comorbidities did not change the benefits seen with lebrikizumab, according to data published in Annals of Allergy, Asthma & Immunology ...

Antibiotic treatment in the first week of life was associated with food allergies at ages 9-12, according to a Dutch study.